查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2091117

全球前列腺特異性抗原 (PSA) 檢測市場規模、佔有率、趨勢和成長分析報告（2026-2034 年）

Global Prostate Specific Antigen (PSA) Testing Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球前列腺特異性抗原 (PSA) 檢測市場預計將從 2025 年的 52.4 億美元成長至 2034 年的 147.4 億美元，2026 年至 2034 年的複合年成長率 (CAGR) 為 12.18%。該市場穩步擴張的原因在於全球對前列腺癌早期檢測重要性的認知不斷提高。 PSA 檢測是目前最常使用的前列腺異常早期篩檢方法之一，有助於及時治療性介入，從而改善患者預後。人口老化、前列腺癌發病率上升以及醫療保健成本不斷增加是推動已開發國家和新興國家醫療保健系統市場持續成長的關鍵因素。

預防醫學的日益普及和定期體檢計劃的廣泛應用，顯著推動了PSA檢測的需求。診斷技術的進步提高了檢測的準確性，檢測基礎設施的擴充也使檢測更加便捷。政府加強推廣癌症篩檢，部分國家推出了優惠的保險報銷政策，以及活性化的公眾宣傳宣傳活動，都鼓勵更多人定期進行前列腺健康檢查，從而促進了市場的持續成長。

受生物標記研究和個人化診斷持續進步的推動，PSA檢測市場前景依然樂觀。高靈敏度檢測方法的開發，結合人工智慧輔助的診斷結果解讀，有望提升臨床決策水準。此外，發展中地區醫療服務覆蓋範圍的擴大、癌症診斷領域投資的增加以及檢測技術的不斷創新，都將在預測期內為生產商創造巨大的成長機會。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球前列腺特異性抗原 (PSA) 檢測市場：按類型分類

  • 市場分析、洞察與預測
  • 臨床實驗室改善法案 (CLIA)（CLIA豁免檢測、非CLIA檢測）
  • 酵素免疫分析法（ELISA）（夾心ELISA試劑盒、競爭性ELISA試劑盒）
  • 螢光免疫分析(FIA)（即時檢測 FIA、檢查室FIA）
  • 其他類型（化學冷光免疫檢測（CLIA）、免疫檢測（RIA））

第5章 全球前列腺特異性抗原 (PSA) 檢測市場：依應用領域分類

  • 市場分析、洞察與預測
  • 篩檢
  • 治療後後續觀察
  • 其他用途

第6章 全球前列腺特異性抗原 (PSA) 檢測市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 診斷中心
  • 研究機構
  • 其他最終用戶

第7章 全球前列腺特異性抗原（PSA）檢測市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Siemens AG
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Becton Dickinson And Company
    • PerkinElmer Inc
    • Beckman Coulter Inc
    • Bio-Rad Laboratories Inc
    • DiaSorin SpA
    • OPKO Health Inc
    • Meso Scale Diagnostics LLC
    • Tosoh America Inc
    • Fujirebio Europe NV
    • Boditech Med Inc
    • DRG International Inc
    • Accuquik Inc
簡介目錄
Product Code: VMR112118714

The global prostate specific antigen (PSA) testing market size is expected to reach USD 14.74 Billion in 2034 from USD 5.24 Billion in 2025, growing at a CAGR of 12.18 during 2026-2034.This market is expanding steadily as awareness regarding early detection of prostate cancer continues to increase worldwide. PSA testing remains one of the most commonly used screening methods for identifying prostate abnormalities at an early stage, allowing timely intervention and improved patient outcomes. Rising aging populations, increasing incidence of prostate cancer, and growing healthcare expenditure are among the primary factors contributing to sustained market growth across developed and emerging healthcare systems.

Growing adoption of preventive healthcare practices and routine health screening programs is significantly boosting demand for PSA testing. Technological improvements in diagnostic assays have enhanced testing accuracy, while expanding laboratory infrastructure has improved accessibility. Increasing government initiatives promoting cancer screening, favorable reimbursement policies in several countries, and rising public awareness campaigns are encouraging more individuals to undergo regular prostate health evaluations, supporting continuous market expansion.

The future outlook for the PSA testing market remains favorable with ongoing advancements in biomarker research and personalized diagnostics. Development of highly sensitive testing methods combined with artificial intelligence-assisted diagnostic interpretation is expected to improve clinical decision-making. Expanding healthcare access in developing regions, increasing investments in cancer diagnostics, and continuous innovation in laboratory technologies will create substantial growth opportunities for manufacturers throughout the forecast period.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Clinical Laboratory Improvement Amendments (CLIA) (CLIA Waived Tests, Non-CLIA Tests)
  • Enzyme-Linked Immunosorbent Assay (ELISA) (Sandwich ELISA Kits, Competitive ELISA Kits)
  • Fluorescence Immunoassay (FIA) (Point-Of-Care FIA, Laboratory-Based FIA)
  • Other Types (Chemiluminescent Immunoassay (CLIA), Radioimmunoassay (RIA))

By Application

  • Screening
  • Post-Treatment Monitoring
  • Other Applications

By End User

  • Hospitals
  • Diagnostic Centers
  • Research Institutes
  • Other End Users

COMPANIES PROFILED

  • Siemens AG, F. Hoffmann-La Roche AG, Abbott Laboratories, Becton Dickinson and Company, PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., DiaSorin S.p.A., OPKO Health Inc., Meso Scale Diagnostics LLC, Tosoh America Inc., Fujirebio Europe NV, Boditech Med Inc., DRG International Inc., Accuquik Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROSTATE SPECIFIC ANTIGEN (PSA) TESTING MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Clinical Laboratory Improvement Amendments (CLIA) (CLIA Waived Tests, Non-CLIA Tests) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Enzyme-Linked Immunosorbent Assay (ELISA) (Sandwich ELISA Kits, Competitive ELISA Kits) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Fluorescence Immunoassay (FIA) (Point-Of-Care FIA, Laboratory-Based FIA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Other Types (Chemiluminescent Immunoassay (CLIA), Radioimmunoassay (RIA)) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROSTATE SPECIFIC ANTIGEN (PSA) TESTING MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Post-Treatment Monitoring Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROSTATE SPECIFIC ANTIGEN (PSA) TESTING MARKET: BY END USER 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End User
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Diagnostic Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROSTATE SPECIFIC ANTIGEN (PSA) TESTING MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Application
    • 7.2.3 By End User
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Application
    • 7.3.3 By End User
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Application
    • 7.4.3 By End User
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Application
    • 7.5.3 By End User
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Application
    • 7.6.3 By End User
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROSTATE SPECIFIC ANTIGEN (PSA) TESTING INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Siemens AG
    • 9.2.2 F. Hoffmann-La Roche AG
    • 9.2.3 Abbott Laboratories
    • 9.2.4 Becton Dickinson And Company
    • 9.2.5 PerkinElmer Inc
    • 9.2.6 Beckman Coulter Inc
    • 9.2.7 Bio-Rad Laboratories Inc
    • 9.2.8 DiaSorin S.p.A
    • 9.2.9 OPKO Health Inc
    • 9.2.10 Meso Scale Diagnostics LLC
    • 9.2.11 Tosoh America Inc
    • 9.2.12 Fujirebio Europe NV
    • 9.2.13 Boditech Med Inc
    • 9.2.14 DRG International Inc
    • 9.2.15 Accuquik Inc